PTGS2 and chronic obstructive pulmonary disease: UPF17 increased (p = 0.007) but UPF1 decreased (p = 0.018) COX-2 expression amongst patients with a history of ≥2 moderate or ≥1 severe AE-COPD within the last year (Figure 1B, middle panel).